Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of Dark Agouti rats
Authors:
- Shizuo NarimatsuSNShizuo Narimatsu
- Shoichi FujitaSFShoichi Fujita
- Yasuhiro MasubuchiYMYasuhiro Masubuchi
- Shin UmedaSUShin Umeda
- 6 November 1991
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 42 (11) , 2241-2244
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranololBiochemical Pharmacology, 1991
- Multiple pathways of propranolol's metabolism are inhibited by debrisoquinClinical Pharmacology & Therapeutics, 1989
- The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA ratsBiochemistry, 1989
- Bunitrolol metabolism and its inhibition by cimetidineJournal of Pharmacy and Pharmacology, 1988
- Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activitiesBiochemical Pharmacology, 1985
- Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolismBiochemistry, 1984
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strainsJournal of Pharmacy and Pharmacology, 1981
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Comparative partial agonist activity of β‐adrenoceptor antagonistsBritish Journal of Pharmacology, 1972